{"protocolSection": {"identificationModule": {"nctId": "NCT04450108", "orgStudyIdInfo": {"id": "FeNO US Monitoring Study"}, "organization": {"fullName": "Bosch Healthcare Solutions GmbH", "class": "INDUSTRY"}, "briefTitle": "Vivatmo Pro\u2122 for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients", "officialTitle": "Clinical Study of the Vivatmo Pro\u2122 for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients Responding to Inhaled Corticosteroid (ICS) Treatment"}, "statusModule": {"statusVerifiedDate": "2022-05", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-09-08", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2020-12-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-04-13", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-06-24", "studyFirstSubmitQcDate": "2020-06-24", "studyFirstPostDateStruct": {"date": "2020-06-29", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-04-12", "resultsFirstSubmitQcDate": "2022-05-11", "resultsFirstPostDateStruct": {"date": "2022-06-06", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-05-11", "lastUpdatePostDateStruct": {"date": "2022-06-06", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Bosch Healthcare Solutions GmbH", "class": "INDUSTRY"}, "collaborators": [{"name": "Global BioClinical", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": true, "isUnapprovedDevice": true, "isUsExport": false}, "descriptionModule": {"briefSummary": "This is a multi-center study to evaluate fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro in adult and pediatric subjects.", "detailedDescription": "Subjects will be screened, enrolled and tested at Study Visit #1 and then prescribed inhaled corticosteroid (ICS) treatment as per routine clinical care. Subjects will return for Study Visit #2 in two weeks and repeat fractional exhaled nitric oxide (FeNO) measured with the Vivatmo pro"}, "conditionsModule": {"conditions": ["Asthma", "Asthma in Children"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 122, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Test Cohort", "type": "EXPERIMENTAL", "description": "Subjects age 7 to 80 with asthma", "interventionNames": ["Diagnostic Test: Vivatmo pro FeNO Test"]}], "interventions": [{"type": "DIAGNOSTIC_TEST", "name": "Vivatmo pro FeNO Test", "description": "Breath gas analysis", "armGroupLabels": ["Test Cohort"], "otherNames": ["Fractional exhaled nitric oxide (FeNo)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in FeNO Value", "description": "Change in FeNO value before and after inhaled corticosteroid treatment", "timeFrame": "14 days"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Subject is 7 to 80 years of age.\n2. Has asthma\n3. Has been identified as a candidate for inhaled corticosteroid (ICS) treatment\n4. Is willing and able to perform Vivatmo pro\u2122 testing\n\nExclusion Criteria:\n\n1. Subject has used corticosteroids prior to enrollment.\n2. Subject has other current serious medical conditions\n3. Subject has not been clinically stable for at least 2 weeks prior to the study\n4. Subject is unwilling or unable to perform Vivatmo pro testing", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "7 Years", "maximumAge": "80 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Klaus Mueller", "affiliation": "Bosch Healthcare", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Clinical Research Center of Alabama", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Kern Research, Inc.", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Chesapeake Clinical Research, Inc.", "city": "White Marsh", "state": "Maryland", "zip": "21162", "country": "United States", "geoPoint": {"lat": 39.38372, "lon": -76.43218}}, {"facility": "The Clinical Research Center, LLC", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "North Carolina Clinical Research", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Allergy Asthma Research Institute", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Test Cohort", "description": "Subjects age 7 to 80 with asthma\n\nVivatmo pro FeNO Test: Breath gas analysis"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "122"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "120"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Test Cohort", "description": "Subjects age 7 to 80 with asthma\n\nVivatmo pro FeNO Test: Breath gas analysis"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "114"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "34.3", "spread": "16.9"}]}]}]}, {"title": "Age, Customized", "populationDescription": "Addition of number adult and children participants covers number of overall participants", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"title": "Adults", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "87"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "41.4", "spread": "13.6"}]}]}, {"title": "Children", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "27"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "12.6", "spread": "2.5"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "114"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "60"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "54"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "114"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "16"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "98"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "114"}]}]}]}, {"title": "Fractional exhaled nitric oxide", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "ppb", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "114"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "31", "lowerLimit": "17", "upperLimit": "76"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in FeNO Value", "description": "Change in FeNO value before and after inhaled corticosteroid treatment", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "percent change", "timeFrame": "14 days", "groups": [{"id": "OG000", "title": "Test Cohort", "description": "Subjects age 7 to 80 with asthma\n\nVivatmo pro FeNO Test: Breath gas analysis"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "120"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-26.1", "lowerLimit": "-32.5", "upperLimit": "-19.0"}]}]}], "analyses": [{"groupIds": ["OG000"], "groupDescription": "Since the effect size of the change (mean change / standard deviation) is on the order of 1 (resulting in N=10 and 13 for power = 80% and 90%, respectively) and therefore large, the sample size is not determined by the primary objective but by the necessity to achieve representative data of FeNO measurement data over all age groups, measurement ranges (\\<, \u2265 cut off) and sites. Thus, 120 subjects will be recruited.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "The change of FeNO values will be estimated in ANCOVA with baseline values as the covariable and will be reported as percent change together with the 95%-confidence interval.", "pValue": "<0.001", "statisticalMethod": "ANCOVA"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "4 months", "eventGroups": [{"id": "EG000", "title": "Test Cohort", "description": "Subjects age 7 to 80 with asthma\n\nVivatmo pro FeNO Test: Breath gas analysis", "deathsNumAffected": 0, "deathsNumAtRisk": 120, "seriousNumAffected": 0, "seriousNumAtRisk": 120, "otherNumAffected": 0, "otherNumAtRisk": 120}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Dr. Klaus M\u00fcller, Study director", "organization": "Bosch Healthcare Solutions", "email": "klaush.mueller@de.bosch.com", "phone": "+49 160 90816081"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-09-25", "uploadDate": "2022-04-08T11:23", "filename": "Prot_SAP_000.pdf", "size": 475499}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-05-09", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000009569", "term": "Nitric Oxide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000016166", "term": "Free Radical Scavengers"}, {"id": "D000000975", "term": "Antioxidants"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045462", "term": "Endothelium-Dependent Relaxing Factors"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000064426", "term": "Gasotransmitters"}, {"id": "D000020011", "term": "Protective Agents"}], "browseLeaves": [{"id": "M12507", "name": "Nitric Oxide", "asFound": "Side effects", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M4292", "name": "Antioxidants", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M25496", "name": "Endothelium-Dependent Relaxing Factors", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M21869", "name": "Protective Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}